Alnylam Pharmace. buy tamam
Start price
20.09.17
/
50%
€87.81
Target price
20.09.17
€76.67
Performance (%)
7.87%
End price
20.09.17
€94.72
Summary
This prediction ended on 20.09.17 with a price of €94.72. With a performance of 7.87%, the BUY prediction by tamam for Alnylam Pharmace. closed with a slight gain. tamam has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -4.688% | -4.688% | 4.343% | 27.435% |
| iShares Core DAX® | 0,46 % | -2,00 % | 9,98 % | 58,55 % |
| iShares Nasdaq 100 | -1,79 % | -5,74 % | -0,78 % | 80,51 % |
| iShares Nikkei 225® | 5,12 % | 9,09 % | 28,82 % | 62,78 % |
| iShares S&P 500 | -1,76 % | -3,67 % | -0,54 % | 54,39 % |
Comments by tamam for this prediction
In the thread Alnylam Pharmace. diskutieren
tamam stimmt der Buy-Einschätzung von melinda zu
tamam stimmt am 20.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 85$ zu.
Überschrift: pharma